Vital Signsby BridgeheadAll voices

01  Voice · Academic · Rare diseases

Dr. Stanley Crooke: no licensed photograph is held, so the academic plate is shown instead.
Academic

Dr. Stanley Crooke

Founder of Ionis Pharmaceuticals, CNBC Advisory Board member

Press citations per month · linked articles
1
0
0
0
0
0
0
0
0
0
0
Jan 2026FebMarAprMayJuneJulyAugSeptOctNovto date
1

press citation on 1 topic since 30 Jan 2026 · last quoted 30 Jan 2026

02  Quoted on · 1 of 29 topics

Open the topic

Dr. Stanley Crooke: key facts

Kind of voice
Academic
Role
Founder of Ionis Pharmaceuticals, CNBC Advisory Board member
Quoted on
Rare diseases
Tracked press citations
1
Most recently quoted
30 Jan 2026

04  The signal · where Dr. Stanley Crooke sits on rare diseases

Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.

Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.

  1. 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
  2. 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
  3. 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
  4. 25=Dorte X. GramSector leaderfounder and CSO of Pila Pharma1
  5. 25=Hans QuidingAcademicPila Pharma's scientific expert in pain management1
  6. 25=Dr. Stanley CrookeAcademicFounder of Ionis Pharmaceuticals, CNBC Advisory Board member1
  7. 25=Mary NicholsonSector leaderhead of advocacy at Debra, the national charity for EB1
  8. 25=Emma MacleodAcademicPrincipal Investigator for Portsmouth Hospitals University NHS Trust1

Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →

05  On the record · press

What Dr. Stanley Crooke has said

By outlet · linked articles
  • cnbc.com1

Verbatim

“The FDA defines rare disease as a patient population of 200,000. But we now know that there are many, many pathogenic mutations that produce disease in far fewer patients ... And our focus is on these patients, because they have no hope.”
Founder of Ionis Pharmaceuticals, CNBC Advisory Board member · Rare diseases · cnbc.com · 30 Jan 2026 · Read the article

Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.